{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:05:38Z","timestamp":1772035538013,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Low dose factor VIII prophylactic therapy in hemophilia has not been well established till date. This randomized controlled trial compared the efficacy of twice vs. thrice weekly schedule of low dose prophylactic factor VIII in children with hemophilia A as evaluated by the bleeding rate and clinico-radiological evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty-three children with severe hemophilia A (\u226418\u2009years) were randomized into two groups. Baseline evaluation included detailed history, clinical (HJHS 2.1 score and FISH score) and radiological examination (Pettersson score and ultrasound score). Group 1 received twice weekly factor VIII prophylaxis while group 2 received thrice weekly factor VIII prophylaxis, the dose being 10\u2009U\/kg in both groups. All participants were followed up over next 6\u2009months to one year. Data regarding acute bleeding episodes and repeat clinico-radiological assessment at the end of follow up were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analyzed 14 children in twice weekly prophylaxis group and 16 children in thrice weekly prophylaxis group. Statistically insignificant difference was found between the bleeding rates in both the groups after prophylaxis with the median values of monthly bleeding rate being 0.17 and p-value of 0.79. The differences between the initial and final clinical and radiological scores within each group were found to be statistically significant. There was no significant difference in the clinical and radiological scores in between the groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Twice weekly FVIII therapy is effective, easily administered prophylactic schedule to prevent long-term complications of hemophilia A.<\/jats:p><jats:p>Lay summary<\/jats:p><jats:p>Hemophilia A is one of the most common congenital coagulation factor deficiencies. Low dose factor VIII prophylaxis is recommended for hemophilia in resource-poor settings to reduce the bleeding episodes and improve the quality of life, although the optimal schedule for the same has not been well established. A randomized controlled trial on 33 children with hemophilia A (\u226418\u2009years) was done to compare the efficacy of twice versus thrice weekly schedule of prophylactic factor VIII. Group 1 received twice weekly factor VIII prophylaxis while group 2 received thrice weekly factor VIII prophylaxis, the dose in both groups being 10\u2009U\/kg. They were evaluated by the bleeding rate and clinical (HJHS 2.1 score and FISH score) and radiological scores (Pettersson score and ultrasound score). All participants were followed up over next 6\u2009months to one year. Data regarding acute bleeding episodes and repeat clinico-radiological assessment at end of follow up were recorded. When analyzed, statistically insignificant difference was found between the bleeding rates after the two prophylaxis regimes. There was a significant improvement between initial and final clinical and radiological scores in both the groups and no difference was recorded in between the groups. To conclude, twice weekly FVIII therapy is effective, easily administered prophylactic schedule to prevent long-term complications of hemophilia A.<\/jats:p><\/jats:sec>","DOI":"10.1093\/tropej\/fmac039","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T23:32:34Z","timestamp":1653089554000},"source":"Crossref","is-referenced-by-count":5,"title":["Twice Weekly Vs. Thrice Weekly Low-Dose Prophylactic Factor VIII Therapy in Children with Hemophilia A: An Open Label Randomized Trial"],"prefix":"10.1093","volume":"68","author":[{"given":"Sunil","family":"Gomber","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, New Delhi, 110095, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7122-3584","authenticated-orcid":false,"given":"Gorika","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, New Delhi, 110095, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Dewan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, New Delhi, 110095, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalendra","family":"Upreti","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, New Delhi 110095, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Sikka","sequence":"additional","affiliation":[{"name":"Department of Pathology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, New Delhi 110095, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"2022052023314493700_fmac039-B1","first-page":"2384","volume-title":"Nelson Textbook of Pediatrics","author":"Scott","year":"2016","edition":"20th edn"},{"key":"2022052023314493700_fmac039-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"2022052023314493700_fmac039-B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.0954-6820.1962.tb18849.x","article-title":"A clinical and medico-social study of haemophilia in Sweden","volume":"379","author":"Ramgren","year":"1962","journal-title":"Acta Med Scand Suppl"},{"key":"2022052023314493700_fmac039-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","volume":"36","author":"Ahlberg","year":"1965","journal-title":"Acta Orthop Scand Suppl"},{"key":"2022052023314493700_fmac039-B6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000208852","article-title":"Prophylaxis of joint hemorrhages in hemophilia","volume":"41","author":"Van Creveld","year":"1969","journal-title":"Acta Haematol"},{"key":"2022052023314493700_fmac039-B7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/archinte.1970.00310060082008","article-title":"Hemophilia prophylaxis with factor VIII concentrate","volume":"125","author":"Kasper","year":"1970","journal-title":"Arch Intern Med"},{"key":"2022052023314493700_fmac039-B8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"2022052023314493700_fmac039-B9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"2022052023314493700_fmac039-B10","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/pbc.24340","article-title":"Hemophilia and prophylaxis","volume":"60(","author":"Ljung","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2022052023314493700_fmac039-B11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/2040620712440007","article-title":"New treatments in hemophilia: insights for the clinician","volume":"3","author":"Knobe","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"2022052023314493700_fmac039-B12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1999","journal-title":"Br J Haematol"},{"key":"2022052023314493700_fmac039-B13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatr Scand"},{"key":"2022052023314493700_fmac039-B14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2516.2010.02318.x","article-title":"Prophylaxis in the haemophilia population","volume":"16","author":"Blanchette","year":"2010","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ejh.12617","article-title":"Managing haemophilia for life: 5th Haemophilia Global Summit","volume":"95","author":"Hermans","year":"2015","journal-title":"Eur J Haematol"},{"key":"2022052023314493700_fmac039-B16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia\u2014a success story from a resource limited country","volume":"22","author":"Verma","year":"2016","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2516.2010.02348.x","article-title":"Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China","volume":"17","author":"Wu","year":"2011","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2516.2012.02926.x","article-title":"Short-term low-dose secondary prophylaxis for severe\/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there is obstacle in its execution: a multi-centre pilot study in China","volume":"19","author":"Tang","year":"2013","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-0609.1977.tb01528.x","article-title":"Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study","volume":"30","author":"Schimpf","year":"1977","journal-title":"Scand J Haematol Suppl"},{"key":"2022052023314493700_fmac039-B20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/acr.20353","article-title":"Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score","volume":"63","author":"Feldman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022052023314493700_fmac039-B21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2516.2011.02671.x","article-title":"Recommendations for assessment, monitoring and follow-up of patients with haemophilia","volume":"18","author":"de Moerloose","year":"2012","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2516.2005.01142.x","article-title":"Functional independence score in haemophilia: a new performance-based instrument to measure disability","volume":"11","author":"Poonnoose","year":"2005","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2516.2007.01508.x","article-title":"Psychometric analysis of the Functional Independence Score in Haemophilia (FISH)","volume":"13","author":"Poonnoose","year":"2007","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B24","first-page":"325","volume-title":"Human Blood Coagulation: Haemostasis and Thrombosis","author":"Biggs","year":"1976"},{"key":"2022052023314493700_fmac039-B25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1201\/9781498713016","volume-title":"Hemostasis and Thrombosis","author":"DeLoughery","year":"2004"},{"key":"2022052023314493700_fmac039-B26","first-page":"153","article-title":"A radiologic classification of hemophilic arthropathy","author":"Pettersson","year":"1980","journal-title":"Clin Orthop Relat Res"},{"key":"2022052023314493700_fmac039-B27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2516.2010.02380.x","article-title":"Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score","volume":"17","author":"Melchiorre","year":"2011","journal-title":"Haemophilia"},{"key":"2022052023314493700_fmac039-B28","first-page":"243","article-title":"Prophylactic treatment for hemophilia A patients: a pilot study","volume":"26","author":"Chuansumrit","year":"1995","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2022052023314493700_fmac039-B29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2516.2001.00471.x","article-title":"What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?","volume":"7","author":"Petrini","year":"2001","journal-title":"Haemophilia"}],"container-title":["Journal of Tropical Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/68\/3\/fmac039\/43775968\/fmac039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/68\/3\/fmac039\/43775968\/fmac039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:08:00Z","timestamp":1700611680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tropej\/article\/doi\/10.1093\/tropej\/fmac039\/6589882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/tropej\/fmac039","relation":{},"ISSN":["0142-6338","1465-3664"],"issn-type":[{"value":"0142-6338","type":"print"},{"value":"1465-3664","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,5]]},"article-number":"fmac039"}}